Literature DB >> 24448234

Calculated computed tomography volumes of lacrimal glands and comparison to clinical findings in patients with thyroid eye disease.

Chad M Bingham1, Matheson A Harris, Tony Realini, John Nguyen, Jeffery P Hogg, Jennifer A Sivak-Callcott.   

Abstract

PURPOSE: To describe the range of lacrimal gland volumes on CT in Caucasian patients with thyroid eye disease (TED) and to correlate with clinical findings.
METHODS: With institutional review board approval, 125 orbital CT scans for TED were reviewed. OsiriX software was used to calculate the volume of the lacrimal gland. Comparison of the volumes was made with previously published results of the normal population. Patient race, gender, smoking status, diplopia, tearing, exophthalmometry, superficial punctate keratitis (SPK), lagophthalmos, restriction in motility, and VISA score were collected.
RESULTS: The mean volume of the lacrimal gland in patients with TED was 0.890 cm in right orbits (standard deviation [SD] 0.348), 0.851 cm in left orbits (SD 0.350), with no significant difference between right and left (p = 0.311). The mean volume was 0.811 cm in right male orbits (SD 0.386) and 0.911 cm in right female orbits (SD 0.335), with no significant difference between men and women (p = 0.774). These findings were confirmed in an analysis of left orbits. The volume of right and left orbits correlated well (r = 0.777, p < 0.0001). The lacrimal gland volume in patients with TED was greater compared with the normal population using a 2-sample t test (p < 0.0001). Exophthalmometry (right: r = 0.225, p = 0.0115; left: r = 0.267, p = 0.0026) and subjective tearing (right: r = 0.226, p = 0.0138; left: r = 0.197, p = 0.0322) correlated with lacrimal gland volume.
CONCLUSIONS: This study is the first to report the volume of the lacrimal gland calculated on CT scan for patients with TED. The lacrimal gland is larger in patients with TED and correlates with subjective tearing and exophthalmometry.

Entities:  

Mesh:

Year:  2014        PMID: 24448234     DOI: 10.1097/IOP.0000000000000015

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  16 in total

Review 1.  Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.

Authors:  Faraat Ali; Anushma Chorsiya; Varisha Anjum; Asad Ali
Journal:  Int Ophthalmol       Date:  2021-01-22       Impact factor: 2.031

2.  Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy.

Authors:  Jun Soo Byun; Nam Ju Moon; Jeong Kyu Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-12       Impact factor: 3.117

3.  Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues.

Authors:  Hao Hu; Xiao-Quan Xu; Lu Chen; Wen Chen; Qian Wu; Huan-Huan Chen; Hui Zhu; Hai-Bin Shi; Fei-Yun Wu
Journal:  Endocrine       Date:  2020-06-05       Impact factor: 3.633

Review 4.  Extraocular muscle enlargement.

Authors:  Khizar Rana; Valerie Juniat; Sandy Patel; Dinesh Selva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.535

5.  Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity.

Authors:  Cesare Gagliardo; Stefano Radellini; Raffaella Morreale Bubella; Giorgia Falanga; Pierina Richiusa; Maria Vadalà; Alessandro Ciresi; Massimo Midiri; Carla Giordano
Journal:  Eur Radiol       Date:  2020-01-17       Impact factor: 5.315

6.  A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.

Authors:  Stephanie Hiu Ling Poon; Janice Jing-Chee Cheung; Kendrick Co Shih; Yau Kei Chan
Journal:  Rev Endocr Metab Disord       Date:  2022-01-23       Impact factor: 6.514

7.  Usefulness of readout-segmented EPI-based diffusion tensor imaging of lacrimal gland for detection and disease staging in thyroid-associated ophthalmopathy.

Authors:  Lu Chen; Hao Hu; Wen Chen; Qian Wu; Jiang Zhou; Huan-Huan Chen; Xiao-Quan Xu; Hai-Bin Shi; Fei-Yun Wu
Journal:  BMC Ophthalmol       Date:  2021-07-20       Impact factor: 2.209

Review 8.  Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.

Authors:  Jesús Barrio-Barrio; Alfonso L Sabater; Elvira Bonet-Farriol; Álvaro Velázquez-Villoria; Juan C Galofré
Journal:  J Ophthalmol       Date:  2015-08-17       Impact factor: 1.909

9.  Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.

Authors:  Alexander D Blandford; Dalia Zhang; Rao V Chundury; Julian D Perry
Journal:  Expert Rev Ophthalmol       Date:  2017-01-27

10.  Diagnosis and stage of Graves' ophthalmopathy: Efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging.

Authors:  Hao Hu; Xiao-Quan Xu; Fei-Yun Wu; Huan-Huan Chen; Guo-Yi Su; Jie Shen; Xun-Ning Hong; Hai-Bin Shi
Journal:  Exp Ther Med       Date:  2016-05-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.